-

Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations

ATLANTA--(BUSINESS WIRE)--Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising.

As a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its competitors. But when competitors make allegations that are without merit, Axion must robustly defend itself.

At issue are Agilent Technologies, Inc.’s spurious allegations of false advertising and claims that certain of Axion’s live-cell analysis products infringe three Agilent patents. In rebuttal, Axion rejects any claims of patent infringement and stands by the technological capabilities of its products.

Axion is confident that it does not infringe Agilent’s patents and that those patents will ultimately be proven invalid. Axion looks forward to vindicating its rights in court and obtaining a successful outcome against Agilent. Axion BioSystems will continue to advance the frontiers of live-cell analysis as a market innovator to accelerate biomedical discoveries.

About Axion BioSystems

Axion BioSystems, Inc. is a leading life science company focused on next-generation live-cell analysis tools for biomedical research and drug discovery. With innovative systems that monitor complex cellular activity in real time without disturbing the underlying biology, Axion’s technology accelerates scientific discovery with streamlined workflows providing more complete datasets. Headquartered in Atlanta, Georgia, USA, the company has more than 180 employees worldwide. www.axionbiosystems.com

Contacts

Mike Clements
Vice President Marketing, Axion BioSystems
media@axionbio.com

Industry:

Axion BioSystems, Inc.

Release Summary
Market disruptor Axion BioSystems rejects Agilent Technologies, Inc. allegations.
Release Versions
English
Hashtags
#Biotech
#ImmunoOncology
#Neuroscience
#StemCells

Contacts

Mike Clements
Vice President Marketing, Axion BioSystems
media@axionbio.com

Social Media Profiles
Axion BioSystems on LinkedIn
Axion BioSystems on Twitter
Axion BioSystems YouTube
More News From Axion BioSystems, Inc.

Maestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND Program

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced that the FDA's Center for Drug Evaluation and Research (CDER) has accepted the company’s letter of intent (LOI) into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Program for its Human iPSC-Cardiomyocyte MEA Assay for Prediction of Clinical Cardiovascular Repolarization Risk. The submission represents the first stem cell-derived, functional cardiac safety assay accepted into the ISTAND program. The ISTAND progr...

Axion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology from CytoTronics

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life sciences tools company focused on cutting-edge live-cell bioelectronic assay and imaging systems, announces the acquisition of the intellectual property and assets of CytoTronics, Inc. The purchase brings novel high-density (HD) electrode array technology developed at Harvard University to Axion’s growing product suite and strengthens Axion’s ability to provide researchers with the most advanced tools for disease research and drug disco...

Harnessing Combined Expertise: STEMCELL Technologies and Axion BioSystems Partner to Streamline Culture and Analysis of Excitable Cells

ATLANTA & VANCOUVER, British Columbia--(BUSINESS WIRE)--Axion BioSystems and STEMCELL Technologies are pleased to announce a strategic partnership that will enable STEMCELL to sell Axion’s state-of-the-art Maestro Pro™ and Maestro Edge™ multielectrode array (MEA) systems within North America and Europe. The industry-leading Maestro MEA systems will also continue to be available for purchase worldwide directly from Axion BioSystems. Through this partnership, Axion and STEMCELL will enable scient...
Back to Newsroom